Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage ...

Providing a better understanding of the underlying determinants of BRAF's oncogenic potential, the new study also paves the way for the optimization of new classes of small molecule inhibitors ...

Poster Abstract number: A095 Title: The paradox-breaker BRAF inhibitor plixorafenib (FORE8394) efficiently inhibits non-V600 mutations and fusions Presentation Session Date/Time: Oct 12, 2023, 12: ...

However, these 'first generation' BRAF inhibitors do not work on all BRAF mutated cancers and in other cases cancers become resistant to the treatment. The new drug, PLX8394, ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal cancer. News & Perspective Tools & Reference CME/CE. More .

Poster Abstract number: 4609 Poster Title: The paradox-breaker BRAF inhibitor plixorafenib (PLX8394; FORE8394) synergizes with MEK inhibitors (MEKi) in BRAF V600 and non-V600 alterations, with ...

Discovery of potential RAF selective back pocket as a promising biological site for BRAF inhibitors targeting resistant melanoma opens the door for a new generation of kinase inhibitors: Design ...

Autophagy inhibition could help patients who develop resistance to BRAF inhibitors, but a new review shows important questions remain. The addition of autophagy inhibitors to BRAF-targeted therapy ...

To the Editor: In their phase 1 trial, Flaherty and colleagues (Aug. 26 issue) 1 report that treatment with a BRAF inhibitor was effective for the majority of patients with metastatic melanomas ...

NEW ORLEANS — BRAF and MEK inhibitors may showed promise as a treatment option for children and adults with histiocytic disorders, according to a presenter here. Langerhans cell histiocytosis ...

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Research , 2019; canres.0040.2019 DOI: 10.1158/0008-5472.CAN-19-0040 Cite This Page : ...

Compared with chemotherapy and immunotherapy, BRAF inhibitors increased the risk for uveitis by 7.52- and 5.68-folds, respectively; the respective risk for severe uveitis rose by 9.53- and 6.40 ...